ABT-888 With or Without Mitomycin in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

Conditions Phase Intervention Type
  • Neoplasms
Phase 1
Drug
mitomycin C
Drug
veliparib

View trial NCT01017640 on www.clinicaltrials.gov

Eligibility

Ages Eligible for Study
18 years and up
Genders Eligible for Study
Both

Keywords

unspecified adult solid tumor, protocol specific

Sponsors

NIH
National Cancer Institute (NCI)
Other
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute

Inclusion Criteria

Exclusion Criteria

Detailed Description

RATIONALE: ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as mitomycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with mitomycin may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of ABT-888 when given with or without mitomycin in treating patients with metastatic, unresectable, or recurrent solid tumors.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01017640

Locations

  • Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
    Columbus, Ohio United States
    (Recruiting)

    Contact info

    Ohio State University Cancer Clinical Trial Matching Service
    866-627-7616